Recruiting

N/A

2

RoW

prednisone,methylprednisone and cyclophosphamide, Rituximab

Beijing Friendship Hospital

Mild Cognitive Impairment, Idiopathic Membranous Nephropathy

09/25

09/25

Recruiting

N/A

60

RoW

Auto CAR-T, Cyclophosphamide,Fludarabine, Leukapheresis

Hebei Senlang Biotechnology Inc., Ltd., Hebei Medical University Fourth Hospital

Plasma Cell Tumors

10/23

10/25

Not yet recruiting

N/A

60

 

Isazomi+cyclophosphamide+ dexamethasone ;Isazomi+dexamethasone

West China Hospital, Sichuan University; West China Hospital, Sichuan University, SCI funding

multiple myeloma

 

 

Recruiting

N/A

20

RoW

CART-19 and 20 cells, Cyclophosphamide, Fludarabine

Henan Cancer Hospital

Non-hodgkin Lymphoma,B Cell

12/25

12/25

Recruiting

N/A

1200

RoW

Corticosteroid, Steroid, Prednisone, Methylprednisone, Prednisolone, Hydroxychloroquine, Cyclophosphamide, Mycophenolate Mofetil, Azathioprine, Tacrolimus, Cyclosporine A, Rituximab, anti-CD20 antibody

Xiqiang Dang, The Children's Hospital Affiliated to Suzhou University, Shandong Provincial Hospital, Guizhou Provincial People's Hospital, LanZhou University, The First Affiliated Hospital of Inner Mongolia Medical College, People's Hospital of Zhangjiajie, Puyang Oilfield General Hospital, The First Affiliated Hospital of Anhui Medical University, Guizhou Maternal and Child Health Care Hospital, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Shenzhen Children's Hospital, The Second Affiliated Hospital of Harbin Medical University, Yichang Central People's Hospital, Xian Children's Hospital, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science & Technology, The First People's Hospital of Yunnan, The First Affiliated Hospital of Xiamen University, The First Affiliated Hospital of Xinxiang Medical College, Shanxi Provincial Maternity and Children's Hospital, Liaocheng People's Hospital, Fujian Provincial Hospital, First Affiliated Hospital of Guangxi Medical University, Second Hospital of Lanzhou University, Guangzhou First People's Hospital, The Second Hospital of Shandong University, Children's Hospital of Hebei Province, Beijing Children's Hospital, Zhengzhou Children's Hospital, The Children's Hospital of Chongqing Medical University, Wuxi Children's Hospital, The Children's Hospital of Fudan University, Shanghai Children's Medical Center, Qilu Children's Hospital of Shandong University

Lupus Nephritis, Children, Steroid, Immunosuppressive Treatment

11/23

11/24

Recruiting

N/A

210

 

1.Pretreatment: If patients with WBC ≥ 30000/L or with severe hepatosplenomegaly or lymph node enlargement then should receive Prednisone 1 mg/kg/d, 3-5 days, or the same amount of Dexamethasone ;2.Induction regimen (4-week FVD regimen): Flumatinib(FM) 600mg Po Qd+ Vindesine(VDS) 4mg/d (D1, 8, 15, 22) + Dexamethasone(DXMS) 20mg/d (D1-4, 8-11, 15-18, 22-25) (bone marrow aspiration and detection of BCR/ABL copies on the 14th and 28th day) ;3. Consolidation therapy (8 weeks, divided into two stages, each stage 4 weeks). CAM regimen [Cyclophosphamide(CTX) 1000mg/m2/d (d1) + Cytarabine(Ara-C) 75 mg/m2/d (d3-6,10-13) + 6-Mercaptopurine(6-MP) 60mg/m2/d Po (d1-14)].F-CAM regimen [FM 600mg mg/m2/d (d1) + CTX 750 mg/m2/d (d1) + Ara-C 75mg/m2/d (d3-6,10-13) + 6-MP 60 ;4.Intensive therapy (1-2 times): Hyper-CVAD-B regimen: MTX 1g/m2 was infused continuously for 24 hours, and Calcium Folinate was given for detoxification per 12 hours. After detoxification, Ara-C 3mg / m2 was given intravenously for 4 times every 12 hours. (if the symptoms of oral mucosal erosion, ulcer and ;5.Transplantation: If the minimal residual disease (MRD) of fusion gene is persistent negative, then autologous hematopoietic stem cell transplantation would be selected (ASCT); otherwise allogeneic hematopoietic stem cell transplantation (allo-HSCT) would be. ;6.Maintenance therapy: allo-HSCT: FM 600mg/d lasts for 1 year;ASCT: FVP regimen 28 days/course, lasting for one year: FM 600mg+VDS 4mg (d1)+Prednisone 1mg/kg/d (d1-5). ;7.Whole course prophylaxis of central nervous system leukemia(CNSL) : Intrathecal injection (MTX 10 mg + Ara-C 50 mg + DXM 10 mg) was performed at least 12-16 times, and patients intending to undergo SCT should complete 4-6 times before SCT.

Department of Hematology, The First Affiliated Hospital of Chongqing Medical University; Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Self-raised

Acute lymphoblastic leukemia with Ph-positive

 

 

Recruiting

N/A

2

RoW

Rituximab, Modified Ponticelli regimen

Beijing Friendship Hospital

Idiopathic Membranous Nephropathy

12/23

12/23

Recruiting

N/A

150

Europe

University Hospital, Gasthuisberg, University Hospital, Antwerp, University Hospital, Ghent, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Cancer, Pregnancy

12/23

12/23

Recruiting

N/A

100

RoW

CD19+22 CAR-T cells, CD19+22 CAR-T

Hebei Senlang Biotechnology Inc., Ltd.

Non-hodgkin's Lymphoma

12/23

12/23

Recruiting

N/A

50

US

CliniMACS Cell Processing System for TCRαβ + T Cell and CD45RA Depleted Peripheral Stem Cell Addback

Children's Hospital of Philadelphia

Acute Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia, Mixed Lineage Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma, Juvenile Myelomonocytic Leukemia

02/25

01/26

Not yet recruiting

N/A

10

RoW

LILRB4 STAR-T cells injection

Institute of Hematology & Blood Diseases Hospital

Acute Myelogenous Leukemia, Chronic Myelomonocytic Leukemia

02/24

08/24

Withdrawn

N/A

12

US

Cyclophosphamide, Cytoxan

Johns Hopkins University

ROHHAD Syndrome

03/24

03/24

Active, not recruiting

N/A

40

US

cyclosporine, Matched Unrelated Donor Hematopoietic Stem Cell Transplant, horse anti-thymocyte globulin (ATG), ATGAM, rabbit anti-thymocyte globulin (ATG), Thymoglobulin, methotrexate, fludarabine, cyclophosphamide, low-dose total body irradiation (TBI), Immunosuppressive Therapy (IST)

Michael Pulsipher, MD

Severe Aplastic Anemia

04/24

04/24

Suspended

N/A

55

US

Short-Term Fasting, Intermittent Fasting, Short-term Intermittent Fasting

Thomas Jefferson University, National Cancer Institute (NCI)

Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma in Situ, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Carcinoma

05/24

05/24

Recruiting

N/A

12

RoW

BGT007H Cell Injection

RenJi Hospital

Tumor Pancreas

03/27

08/27

Recruiting

N/A

100

US

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Systemic Lupus Erythematosus (Sle), Primary Ovarian Insufficiency (Poi)

Not yet recruiting

N/A

200

NA

Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel, Epirubicin, Cyclophosphamide, Docetaxel

Zhejiang Provincial People's Hospital

Breast Cancer, Chemotherapy Effect

06/24

06/25

Not yet recruiting

N/A

210

 

Prednisone ;Cyclophosphamide ;Prednisone ;Cyclophosphamide ;Runfei Huayu recipe ;no

Taizhou Hospital of Traditional Chinese Medicine; Taizhou Hospital of Traditional Chinese Medicine, Jiangsu Administration of Traditional Chinese Medicine

Connective tissue disease merger interstitial lung disease

 

 

Not yet recruiting

N/A

260

 

R-CHOP/R-CDOP regimen (Rituximab, Cyclophosphamide, Hydroxyldaunorubicin/Liposome doxorubicin, Oncovin, Prednisone) ;R-CHOP/R-CDOP (Rituximab, Cyclophosphamide, Hydroxyldaunorubicin/Liposome doxorubicin, Oncovin, Prednisone) Prophylactic treatment with SMZ

The First Affiliated Hospital, Zhejiang University College of Medicine; The First Affiliated Hospital, Zhejiang University College of Medicine, Self-faised funds

B cell lymphoma

 

 

Completed

N/A

44

US

melphalan, Alkeran®, fludarabine, FLUDARA®, thiotepa, Cyclophosphamide, Cytoxan®, Mesna, Mesnex®, Mycophenolate Mofetil, CellCept®, Filgrastim, Neupogen®, Tacrolimus, Prograf®

Memorial Sloan Kettering Cancer Center

Hematologic Malignancy

11/23

11/23

Recruiting

N/A

40

RoW

Rituximab, Cyclophosphamide, and Corticosteroids

St. Petersburg State Pavlov Medical University

Membranous Nephropathy - PLA2R Induced

08/24

08/24

Recruiting

N/A

204

RoW

Pegylated liposomal doxorubicin, duomeisu, Doxorubicin Hydrochloride Liposome Injection, Epirubicin, biaoroubixing, Cyclophosphamid, huanlinxianan, Trastuzumab, qutuozhudankang, Pertuzumab, patuozhudankang, Docetaxel, duoxitasai

Shanghai Pudong Hospital, CSPC Ouyi Pharmaceutical Co., Ltd.

Breast Cancer

09/24

09/25

Recruiting

N/A

50

RoW

CAR-T Autologous T cell injection, CD19 CAR-T, CD20 CAR-T, BCMA CAR-T

Hebei Senlang Biotechnology Inc., Ltd.

Acute Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma

09/24

12/24

Not yet recruiting

N/A

20

NA

blinatumomab

Sichuan University

Leukemia, Lymphoid

09/24

09/24

Recruiting

N/A

164

RoW

Etoposide, VP-16, Cyclophosphamide, CTX

Affiliated Hospital to Academy of Military Medical Sciences

Multiple Myeloma

10/24

10/25

Recruiting

N/A

30

US

Alemtuzumab 0.3 mg, Campath-1H, Cyclophosphamide, Cytoxan, Busulfan, Myerlan, Stem Cell Transplantation, Fludarabine phosphate 40 mg, Fludara, Melphalan, Alkeran, Alemtuzumab 0.2 mg, Campath 1-H, Fludarabine phosphate 30 mg, MESNA, mercaptoethane sulfonate Na (Na being the symbol for sodium), Mesnex

Masonic Cancer Center, University of Minnesota

SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome, Bare Lymphocyte Syndrome, Common Variable Immunodeficiency, Chronic Granulomatous Disease, CD40 Ligand Deficiency, Hyper IgM Syndrome, X-linked Lymphoproliferative Disease, Hemophagocytic Lymphohistiocytosis, Griscelli Syndrome, Chediak-Higashi Syndrome, Langerhan's Cell Histiocytosis

12/25

12/26

Not yet recruiting

N/A

36

 

Low-dose TBI combined with flundarabine, arabinoside and cyclophosphamide (FACT) for allogeneic hematopoietic stem cell transplantation

Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine; Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine., Project and self-financing

Acute leukemia

 

 

Recruiting

N/A

60

 

Rituximab combined with tacrolimus induction + rituximab maintenance ;Rituximab combined with tacrolimus induction + tacrolimus maintenance ;Glucocorticoid combined with cyclophosphamide induction + maintenance

Renji Hospital Affiliated to Shanghai jiao tong university school of medicine; Renji Hospital Affiliated to Shanghai jiao tong university school of medicine, None

Primary Membranous Nephropathy

 

 

Recruiting

N/A

40

RoW

Umbilical Cord Blood Transplantation, Total Body Irradiation/Fludarabine/Busulfan/Cyclophosphamide

The First Affiliated Hospital of Soochow University

Hematopoietic Stem Cell Transplantation, Malignant Hematological Diseases

12/24

05/26

Recruiting

N/A

86

RoW

XC, TPC

Wenjin Yin

Advanced Breast Cancer

02/25

02/27

Recruiting

N/A

92

 

Chidamide Combined with R-CHOP Regimen

Peking University Third Hospital; Peking University Third Hospital, self-funded

lymphoma

 

 

Not yet recruiting

N/A

106

 

Induction remission stage: Glucocorticoid + cyclophosphamide; Maintain remission stage: Hormone + azathioprine / methotrexate / mycophenolate mofetil ;Induction remission stage: Methylprednisolone + intravenous cyclophosphamide or rituximab; Maintain remission stage: Hormone + azathioprine / mycophenolate mofetil / rituximab ;Induction: Methylprednisolone + cyclophosphamide + rituximab + plasma exchange; Maintain: Hormone + azathioprine / mycophenolate mofetil / rituximab ;Induction: Methylprednisolone + intravenous cyclophosphamide; Maintain: Hormone + azathioprine / methotrexate / mycophenolate mofetil

Children's Hospital Affiliated to Chongqing Medical University; Children's Hospital Affiliated to Chongqing Medical University, self-financing

ANCA associated glomerulonephritis

 

 

Recruiting

N/A

300

RoW

ATG, Post-transplantation cyclophosphamide

Peking University People's Hospital, Sanofi

Hematological Malignancy

07/25

12/25

Recruiting

N/A

35

RoW

Rituximab, MabThera, Orelabrutinib, Yinuokai, Pomalidomide, Anyve, Pro-miniCHOP-like regimen, R-miniCHOP-like regimen

The First Affiliated Hospital of Soochow University

Diffuse Large B Cell Lymphoma

07/25

07/26

Not yet recruiting

N/A

110

 

Mefalun+cyclophosphamide+CLAD+Ara-C (MCAC) ;TBI+CLAD+Ara-C (TCAC)

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, drugs

ALL

 

 

Recruiting

N/A

50

RoW

Modified radical mastectomy for breast cancer, neoadjuvant therapy, Systematic treatment

Peking Union Medical College Hospital

Locally Advanced Breast Cancer

10/25

08/26

Active, not recruiting

N/A

132

US

Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Cytology Specimen Collection Procedure, Cytologic Sampling, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Trastuzumab, ABP 980, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, PF-05280014, rhuMAb HER2, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar PF-05280014

Albert Einstein College of Medicine, National Cancer Institute (NCI)

Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer

12/25

12/26

Recruiting

N/A

12

RoW

CAR-GPC3 T cells

RenJi Hospital

Hepatocellular Carcinoma

12/25

12/26

Not yet recruiting

N/A

400

 

Glucocorticoid + 4 doses of rituximab + 2 times of intravenous cyclophosphamide pulse therapy ;Glucocorticoid + 4 doses of rituximab

Children's Hospital Affiliated to Chongqing Medical University; Children's Hospital Affiliated to Chongqing Medical University, National Key R&D Program of China (Grant Number: 2021YFC2702002)

ANCA associated glomerulonephritis

 

 

Not yet recruiting

N/A

264

RoW

MA-BUCY2, Mitoxantrone liposome, cytarabine, busulfan, cyclophosphamide, semustine, anti-thymocyte immunoglobulin, BUCY2, Cytarabine

First Affiliated Hospital Xi'an Jiaotong University

Haploidentical Stem Cell Transplantation, Conditioning

12/25

12/25

Recruiting

N/A

160

RoW

Cytoxan, Etoposide, VP16, Dexamethasone, Cyclosporine (CSA)

shifeng Lou

Hemophagocytic Syndrome

04/26

05/27

Recruiting

N/A

102

RoW

Frozen glove and sock, ddEC-ddT, Chemotherapy

Peking University, CSPC Ouyi Pharmaceutical Co., Ltd.

Breast Cancer

08/26

11/26

Recruiting

N/A

100

Europe

Whole Genome Sequencing, WGS, RNA-Sequencing, Microbiome analysis, ctDNA analysis, TCR-β repertoire sequencing, PBMCs phenotyping, Pembrolizumab, Chemotherapy, Carboplatin, taxane, anthracycline, cyclophosphamide

Vall d'Hebron Institute of Oncology

Triple Negative Breast Cancer

12/26

12/29

Recruiting

N/A

160

 

6*R-CHOP ;6*R-CHOP + 2*R ;6*R-CHOP + 2*R, 6*Obutinib ;8*R-CHOP, 6*Obutinib

The First Affiliated Hospital of Medical College, Zhejiang University; The First Affiliated Hospital of Medical College, Zhejiang University, self-raised

Diffuse large B-cell lymphoma

 

 

Withdrawn

N/A

200

US

Autologous hematopoietic stem cell transplantation, Cyclophosphamide/ATG, Cyclophosphamide/Rituximab

Scripps Health

Multiple Sclerosis, Relapsing-Remitting

07/27

07/27

Recruiting

N/A

60

RoW

Vacuum-assisted biopsy

N.N. Petrov National Medical Research Center of Oncology

Refusal of Breast Surgery in Patients With Breast Cancer With a cCR After NST and a Confirmed Pathological Complete Response (pCR) Using VAB and SLNB

12/27

12/28

Recruiting

N/A

204

Europe

Chemotherapy + follow up, Chemotherapy + ASCT + follow up

Hospices Civils de Lyon

Peripheral T Cell Lymphoma

04/28

04/28